Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system

Prostate

Volumn 74, Issue 13, 2014, Pages 1335-1346

  Arndt, Claudia ^a   Feldmann, Anja ^a,b   Koristka, Stefanie ^a   Cartellieri, Marc ^a,b   Dimmel, Maria ^a   Ehninger, Armin ^a,c   Ehninger, Gerhard ^c   Bachmann, Michael ^a,b,d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

dual targeting; immunotherapy; recombinant antibody; T cell redirection

Indexed keywords

DUAL-TARGETING; IMMUNOTHERAPY; RECOMBINANT ANTIBODY; T CELL REDIRECTION;

ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CELL LINE, TUMOR; GLUTAMATE CARBOXYPEPTIDASE II; GPI-LINKED PROTEINS; HEK293 CELLS; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES;

EID: 84905905975     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22850     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2010; 63 (1): 11-30.
2. Drake CG,. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10 (8): 580-593.
3. Walsh PC, DeWeese TL, Eisenberger MA,. Clinical practice. Localized prostate cancer. N Engl J Med 2007; 357 (26): 2696-2705.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281 (17): 1591-1597.
5. Müller D, Kontermann RE,. Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 2010; 24 (2): 89-98.
6. Stamova S, Koristka S, Keil J, Arndt C, Feldmann A, Michalk I, Bartsch H, Bippes CC, Schmitz M, Cartellieri M, Bachmann M,. Cancer immunotherapy by retargeting of immune effector cells via recombinant bispecific antibody constructs. Antibodies 2012; 1 (2): 172-198.
7. Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ,. A tale of two specificities: Bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 2013; 31 (11): 621-632.
8. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA,. BiTEs: Bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 2005; 10 (18): 1237-1244.
9. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N, Baeuerle PA,. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005; 115 (1): 98-104.
10. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA,. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006; 43 (6): 763-771.
11. Baeuerle PA, Reinhardt C,. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2006; 69 (12): 4941-4944.
12. Stamova S, Feldmann A, Cartellieri M, Arndt C, Koristka S, Apel F, Wehner R, Schmitz M, Bornhäuser M, von Bonin M, Ehninger G, Bartsch H, Bachmann M,. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses. Anal Biochem 2012; 423 (2): 261-268.
13. Nagorsen D, Kufer P, Baeuerle PA, Bargou R,. Blinatumomab: A historical perspective. Pharmacol Ther 2012; 136 (3): 334-342.
14. Portell CA, Wenzell CM, Advani AS,. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol 2013; 5 (Suppl 1): 5-11.
15. + prostate tumor cells. Prostate 2014; DOI 10.1002/pros.22851.
16. Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M,. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: Description of a novel modular targeting system. Leukemia 2014; 28 (1): 59-69.
17. Arndt C, Feldmann A, Koristka S, Michalk I, Cartellieri M, Stamova S, von Bonin M, Bornhäuser M, Ehninger G, Bachmann M,. Redirection of immune effector cells by bispecific antibody systems for the treatment of acute myeloid leukemia [abstract]. Blood 2011; 118: 663-664.
18. Cartellieri M, Arndt C, Feldmann A, von Bonin M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M,. TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity. OncoImmunology 2013; 2 (12): e26770.
19. Arndt C, Cartellieri M, Aliperta R, Koristka S, Michalk I, Bornhäuser M, Ehninger G, Bachmann M, Feldmann A,. Enhancing the efficacy and specificity of antibody-based T cell retargeting strategies against hematological malignancies. Blood 2013; 122: 930.
20. Ghosh A, Heston WD,. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91 (3): 528-539.
21. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP,. Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 2006; 236 (2): 229-238.
22. Raff AB, Gray A, Kast WM,. Prostate stem cell antigen: A prospective therapeutic and diagnostic target. Cancer Lett 2009; 277 (2): 126-132.
23. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ,. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 2009; 69 (10): 1101-1108.
24. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C,. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3 (1): 81-85.
25. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M,. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013; 31 (1): 71-75.
26. Carmo-Fonseca M, Pfeifer K, Schröder HC, Vaz MF, Fonseca JE, Müller WE, Bachmann M,. Identification of La ribonucleoproteins as a component of interchromatin granules. Exp Cell Res 1989; 185 (1): 73-85.
27. Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, Michalk I, Wiefel K, Stamova S, Schmitz M, Ehninger G, Bornhäuser M, Bachmann M,. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun 2013; 42: 105-116.
28. + T cells. J Immunol 2012; 189 (6): 3249-3259.
29. Feldmann A, Stamova S, Bippes CC, Bartsch H, Wehner R, Schmitz M, Temme A, Cartellieri M, Bachmann M,. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: Comparison of different antibody formats. Prostate 2011; 71 (9): 998-1011.
30. Arndt C, Koristka S, Feldmann A, Bartsch H, Bachmann M,. Coomassie-Brilliant Blue staining of polyacrylamide gels. Methods Mol Biol 2012; 869: 465-469.
31. Morgenroth A, Cartellieri M, Schmitz M, Günes S, Weigle B, Bachmann M, Abken H, Rieber EP, Temme A,. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 2007; 67 (10): 1121-1131.
32. Jäger E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jäger D, Oesch F, Knuth A,. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71 (2): 142-147.
33. Davis TA, Czerwinski DK, Levy R,. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999; 5 (3): 611-615.
34. Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch P, Riker AI, Kammula US, Rosenberg SA, Marincola FM,. Short-term kinetics of tumor antigen expression in response to vaccination. J Immunol 2001; 167 (3): 1809-1820.
35. Schreiber RD, Old LJ, Smyth M,. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011; 331 (6024): 1565-1570.
36. Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt C, Stamova S, Michalk I, Töpfer K, Temme A, Kretschmer K, Bornhäuser M, Ehninger G, Schmitz M, Bachmann M,. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol 2012; 188 (3): 1551-1558.
37. Friedrich M, Raum T, Lutterbuese R, Voelkel M, Deegen P, Rau D, Kischel R, Hoffmann P, Brandl C, Schuhmacher J, Mueller P, Finnern R, Fuergut M, Zopf D, Slootstra JW, Baeuerle PA, Rattel B, Kufer P,. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 2012; 11 (12): 2664-2673.
38. Baum V, Bühler P, Gierschner D, Herchenbach D, Fiala GJ, Schamel WW, Wolf P, Elsässer-Beile U,. Antitumor activities of PSMA×CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy 2013; 5 (1): 27-38.
39. Schubert I, Stein C, Fey GH,. Dual-targeting for the elimination of cancer cells with increased selectivity. Antibodies 2012; 1 (1): 2-18.
40. Kügler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, Schubert I, Singer H, Oduncu F, Stockmeyer B, Mackensen A, Fey GH,. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol 2010; 150 (5): 574-586.
41. Schubert I, Kellner C, Stein C, Kügler M, Schwenkert M, Saul D, Mentz K, Singer H, Stockmeyer B, Hillen W, Mackensen A, Fey GH,. A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs 2011; 3 (1): 21-30.
42. Schubert I, Kellner C, Stein C, Kügler M, Schwenkert M, Saul D, Stockmeyer B, Berens C, Oduncu FS, Mackensen A, Fey GH,. A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting. MAbs 2012; 4 (1): 45-56.
43. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gökbuget N, Neumann S, Goebeler M, Viardot A, Stelljes M, Brüggemann M, Hoelzer D, Degenhard E, Nagorsen D, Baeuerle PA, Wolf A, Kufer P,. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119 (26): 6226-6233.